The Effect of Vitamin K2 in Addition to Risedronate on the Patients with Postmenopausal Osteoporosis
Journal of the Korean Academy of Rehabilitation Medicine
;
: 491-495, 2006.
Article
in Korean
| WPRIM
| ID: wpr-722530
ABSTRACT
OBJECTIVE:
To assess the effect of vitamin K2 in addition to risedronate on postmenopausal osteoporosisMETHOD:
We enrolled 21 postmenopausal osteoporosis women (age 65.2+/-7.8 years). Ten subjects received risedronate (35 mg, weekly) and vitamin K2 (45 mg, daily) and eleven subjects only received risedronate. They all received calcium citrate 2,130 mg and vitamin D 600 IU daily. The duration of treatment was 7.7+/-1.4 months. Bone mineral density (BMD) of lumbar spine and both femurs, serum osteocalcin and urine deoxypyridinoline were examined at baseline and after treatment.RESULTS:
After treatment, BMD, serum osteocalcin and urine deoxypyridinoline were improved in each group but there was no statistical difference between the groups.CONCLUSION:
There was no evidence of the benefit of vitamin K2 in addition to risedronate in bone metabolism on postmenopausal osteoporosis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Spine
/
Vitamin D
/
Vitamins
/
Bone Density
/
Osteocalcin
/
Osteoporosis, Postmenopausal
/
Calcium Citrate
/
Vitamin K 2
/
Femur
/
Risedronic Acid
Limits:
Female
/
Humans
Language:
Korean
Journal:
Journal of the Korean Academy of Rehabilitation Medicine
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS